Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T19:18:46.643Z.
Calculation as of: 2026-10-06T19:18:46.643Z.
Quote observation: 2026-10-06T19:15:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9ce6fbcd26cd45408ca5c48bb89acec7413e4f513cf2411d103b895814b8ecfc
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$1.90B
EV/Sales Ratio
18.65x
TTM Avg
32.21x
3Y Avg
52.53x
5Y Avg
140.66x
Market Cap
$1.89B
EV/Sales Ratio
18.27x
TTM Avg
14.52x
3Y Avg
11.97x
5Y Avg
10.42x
Market Cap
$1.92B
EV/Sales Ratio
8.58x
TTM Avg
10.77x
3Y Avg
8.72x
5Y Avg
9.74x
Market Cap
$1.87B
EV/Sales Ratio
N/A
TTM Avg
7.37x
3Y Avg
7.37x
5Y Avg
7.37x
Market Cap
$1.85B
EV/Sales Ratio
0.63x
TTM Avg
0.66x
3Y Avg
0.99x
5Y Avg
1.19x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Trevi Therapeutics, Inc. (TRVI) | $1.89B | N/A | N/A | N/A | N/A |
| Agios Pharmaceuticals, Inc. (AGIO)vs › | $1.90B | 18.65x | 32.21x | 52.53x | 140.66x |
| Immunome, Inc. (IMNM)vs › | $1.89B | N/A | 219.89x | 101.44x | 93.82x |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 18.27x | 14.52x | 11.97x | 10.42x |
| Zymeworks Inc. (ZYME)vs › | $1.89B | 53.19x | 22.33x | 13.89x | 12.70x |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.92B | 8.58x | 10.77x | 8.72x | 9.74x |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.87B | N/A | 7.37x | 7.37x | 7.37x |
| Azenta, Inc. (AZTA)vs › | $1.86B | 2.81x | 1.90x | 2.97x | 4.80x |
| Astrana Health, Inc. (ASTH)vs › | $1.85B | 0.63x | 0.66x | 0.99x | 1.19x |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $1.94B | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
